Evidence map›Paper›PMID 40063733›Full record

ArticleJournal of the American Chemical Society2025

Highly Specific Miniaturized Fluorescent Monoacylglycerol Lipase Probes Enable Translational Research.

Axel Hentsch, Mónica Guberman, Silke Radetzki, Sofia Kaushik, Mirjam Huizenga, Yingfang He, Jörg Contzen, Bernd Kuhn, Jörg Benz, Maria Schippers and 16 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Axel HentschLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.
Mónica GubermanLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.
Silke RadetzkiLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.
Sofia KaushikLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.
Mirjam HuizengaDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0001-8313-0019
Yingfang HeETH Zürich, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Jörg ContzenCharité─Universitätsmedizin Berlin, Center for Stroke Research, 10117 Berlin, Germany.
Bernd KuhnRoche Pharma Research & Early Development, 4070 Basel, Switzerland.ORCID 0000-0002-4301-562X
Jörg BenzRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Maria SchippersRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Jerome PaulLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.
Lea LeibrockRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Ludovic CollinRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Matthias WittwerRoche Pharma Research & Early Development, 4070 Basel, Switzerland.ORCID 0000-0003-1359-4795
Andreas ToppRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Fionn O'HaraRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Dominik HeerRoche Pharma Research & Early Development, 4070 Basel, Switzerland.ORCID 0009-0003-2089-4339
Remo HochstrasserRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Julie BlaisingRoche Pharma Research & Early Development, 4070 Basel, Switzerland.
Jens P von KriesLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.
Linjing MuETH Zürich, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.ORCID 0000-0001-5354-1546
Mario van der SteltDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0002-1029-5717
Philipp MergenthalerCharité─Universitätsmedizin Berlin, Center for Stroke Research, 10117 Berlin, Germany.ORCID 0000-0002-9753-6711
Noa LipsteinLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.ORCID 0000-0002-0755-5899
Uwe GretherRoche Pharma Research & Early Development, 4070 Basel, Switzerland.ORCID 0000-0002-3164-9270
Marc NazaréLeibniz Forschungsinstitut für Molekulare Pharmakologie, Campus Berlin-Buch, 13125 Berlin, Germany.ORCID 0000-0002-1602-2330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoacylglycerol lipase (MAGL) is the pivotal catabolic enzyme responsible for signal termination in the endocannabinoid system. Inhibition of MAGL offers unique advantages over the direct activation of cannabinoid receptors in treating cancer, metabolic disorders, and inflammatory diseases. Although specific fluorescent molecular imaging probes are commonly used for the real-time analysis of the localization and distribution of drug targets in cells, they are almost invariably composed of a linker connecting the pharmacophore with a large fluorophore. In this study, we have developed miniaturized fluorescent probes targeting MAGL by incorporating a highly fluorescent boron-dipyrromethene (BODIPY) moiety into the inhibitor structure that interacts with the MAGL active site. These miniaturized fluorescent probes exhibit favorable drug-like properties such as high solubility and permeability, picomolar potency for MAGL across various species, and high cell selectivity and specificity. A range of translational investigations were conducted, including cell-free fluorescence polarization assays, fluorescence-activated cell sorting analysis, and confocal fluorescence microscopy of live cancer cells, live primary neurons, and human-induced pluripotent stem cell-derived brain organoids. Furthermore, the application of red-shifted analogs or

Indexed as

Boron CompoundsEnzyme InhibitorsFluorescent DyesMonoacylglycerol LipasesTranslational Research, BiomedicalAnimalsHumansMiniaturizationMolecular Structure4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneBoron CompoundsEnzyme InhibitorsFluorescent DyesMonoacylglycerol Lipases

Identifiers

PMID40063733
PMCPMC11951083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.